Quality control of cathepsin-D measurement by the EORTC receptor study group

Benraad, Theo J.; Geurts-Moespot, Anneke; Sala, M; Piffanelli, A; Ross, Alec; Foekens, John A.

doi:10.1016/0959-8049(92)90388-i

Cited by 26 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, there was a good agreement in the results from simultaneous analyses of nine different reference powders prepared for quality assurance surveys. Our findings with the EIA and IRMA protocols (23) extended the observations of the EORTC report (24) regarding the reproducibility of these methods.…”

Section: Discussionsupporting

confidence: 84%

Comparison of cathepsin d determinations in human carcinomas by enzyme immunoassay and immunoradiometric assay

Shaheen

Miseljic

Doering

et al. 1995

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Overexpression of cathepsin D in several types of carcinoma in women appears to be associated with a poor clinical course. In this prospective investigation, cathepsin D levels in 170 specimens of normal and neoplastic human tissues were determined simultaneously by enzyme immunoassay (EIA) and immunoradiometric assay (IRMA) to allow comparisons in multicentric studies, such as cooperative clinical trials. Nonmalignant uteri and specially prepared reference powders were also evaluated. Linear regression analysis between the two assays for all specimens [EIA = 0.87(IRMA)-3.18] demonstrated a correlation coefficient (r) of 0.99 (P < 0.001). When malignancies were categorized by the tissue origin (i.e., breast, uterus, ovary, lymph node, and colon), highly significant correlations were also observed (regressions slopes ranged from 0.58 to 1.02). Intra- and interassay controls conducted for the new EIA procedure gave CV% ranging from 4.4 to 10.2, which was similar to the IRMA test for cathepsin D. The results of both assays correlated well and were highly reproducible. Either assay may be used with confidence that comparable cathepsin D values will be obtained in a wide range of tissue biopsies.

show abstract

Section: Discussionsupporting

confidence: 84%

Comparison of cathepsin d determinations in human carcinomas by enzyme immunoassay and immunoradiometric assay

Shaheen

Miseljic

Doering

et al. 1995

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…Although a general consensus on the routine use of this technique is still far from being achieved, the assessment of cathepsin-D content by means of immunoradiometric assay seems to be likely to give more reliable and comparable inter-study results as assessed by the EORTC Receptor Study Group (Benraad et al, 1992).…”

Section: Discussionmentioning

confidence: 99%

Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis

Ferrandina

Scambia²,

Bardelli³

et al. 1997

Br J Cancer

100

View full text Add to dashboard Cite

Summary Several reports have evaluated the correlation between cathepsin-D and overall survival or disease-free survival in node-negative breast cancer patients. Because conflicting data have so far been reported, a meta-analysis was conducted to clarify this problem. Eleven studies were included in our meta-analysis (total of 2690 patients). A specific meta-analytical methodology for censored data was used, and disease-free survival was the primary end point. Patients with low cathepsin-D levels had a significantly better disease-free survival than patients with high cathepsin-D values (meta-analytical odds ratio from 0.59 to 0.60 over the interval from 1 to 7 years). A secondary metaanalysis conducted exclusively on the data from eight studies based on cytosol assay gave substantially similar results. One limitation of our study is that the cut-off values to define high and low cathepsin-D concentrations were not identical in the various studies included in our meta-analysis (range from 20 to 78 pmol mg-' protein), thus introducing a possible bias in the statistical analysis of the data. However, a simulation based on the well-accepted method of the so-called publication bias showed that more than 100 null studies would be required to lead our results to a statistical level of non-significance. Considering the results of our meta-analysis, we conclude that the data presently available confirm a statistically significant association between high cathepsin-D values and poor disease-free survival in node-negative breast cancer patients. Keywords: meta-analysis; cathepsin D; node-negative breast tumourThe identification of new prognostic factors, more closely related to tumour cell biology, would be of utmost importance for treatment planning in human breast cancer. Improvement in discrimination between low-and high-risk cases is of major concern, particularly in the subset of node-negative patients, 70% of whom are cured by surgery alone and would therefore be spared the cost and potential toxicity of adjuvant chemotherapy (McGuire, 1989;Copper, 1991). To date, several biological factors have been identified and proposed as potential prognostic indexes in human breast cancer. Among these, particular attention has been focused on proteolytic enzymes, such as cathepsin-D and urokinase-type plasminogen activator, which are involved in basement membrane/extracellular matrix degradation and tumour invasiveness and metastasis (Liotta et al, 1991).Cathepsin-D, firstly identified as a 52-kDa oestrogen-regulated glycoprotein (Westley et al, 1970), displays both proteolytic activity in culture and an autocrine mitogenic activity in breast cancer cells (Vignon et al, 1986). The involvement of cathepsin-D in cancer invasion is also supported by the demonstration that transfection of cathepsin-D cDNA into rat tumorigenic cells increases their metastatic potential in nude mice (Garcia et al, 1990). In addition, higher cathepsin-D levels have been found in breast cancer patients with metastatic lymph node involvement than in no...

show abstract

“…The concentration of three cathepsin D forms (52-, 48-and 34-kDa proteins) was determined in breast tumor cytosols obtained for routine ER and PR determination. This was carried out by a future science group radioimmunoassay that has been validated by the EORTC Breast Cancer Cooperative Group [27] and cathepsin D determination was performed according to the instructions provided with the ELSA-CATH-D kit (CIS Bio International, France). Cytosol protein concentration was determined by the Lowry method [28].…”

Section: Methodsmentioning

confidence: 99%

Cathepsin D as an Indicator of Clinical Outcome in Early Breast Carcinoma During the First 3 Years of Follow-Up

Markicevic

Kanjer

Mandušić³

et al. 2013

Biomarkers Med.

View full text Add to dashboard Cite

show abstract

Quality control of cathepsin-D measurement by the EORTC receptor study group

Cited by 26 publications

References 12 publications

Comparison of cathepsin d determinations in human carcinomas by enzyme immunoassay and immunoradiometric assay

Comparison of cathepsin d determinations in human carcinomas by enzyme immunoassay and immunoradiometric assay

Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis

Cathepsin D as an Indicator of Clinical Outcome in Early Breast Carcinoma During the First 3 Years of Follow-Up

Contact Info

Product

Resources

About